Seneca EIS portfolio company Premaitha Health has won multiple contracts for its non-invasive prenatal test on pregnant women across Europe. The deal provides women on the continent privately and in the UK on the NHS with access to its ground breaking IONA test.
The AIM-listed company headquartered at Manchester Science Park has established a new enabling and clinical lab with plans to further increase capacity to meet significant and ongoing demand and substantial new international client enquiries.
Chairman of Premaitha David Evans said: “Premaitha has hit its key milestones as promised at the time of the reverse. We have delivered the world’s first CE-marked diagnostic product, signed contracts across Europe, including launching the first NHS test in the UK, and achieved recognition amongst our peers and key opinion leaders.”